questionsmedicales.fr
Actions chimiques et utilisations
Utilisations spécialisées de produits chimiques
Agents séquestrants
Agents séquestrants : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Agents séquestrants : Questions médicales les plus fréquentes",
"headline": "Agents séquestrants : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Agents séquestrants : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-03",
"dateModified": "2025-04-28",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Agents séquestrants"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Utilisations spécialisées de produits chimiques",
"url": "https://questionsmedicales.fr/mesh/D020313",
"about": {
"@type": "MedicalCondition",
"name": "Utilisations spécialisées de produits chimiques",
"code": {
"@type": "MedicalCode",
"code": "D020313",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.720"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Chélateurs",
"alternateName": "Chelating Agents",
"url": "https://questionsmedicales.fr/mesh/D002614",
"about": {
"@type": "MedicalCondition",
"name": "Chélateurs",
"code": {
"@type": "MedicalCode",
"code": "D002614",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.720.832.500"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Agents chélateurs du calcium",
"alternateName": "Calcium Chelating Agents",
"url": "https://questionsmedicales.fr/mesh/D065096",
"about": {
"@type": "MedicalCondition",
"name": "Agents chélateurs du calcium",
"code": {
"@type": "MedicalCode",
"code": "D065096",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.720.832.500.204"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Agents chélateurs du fer",
"alternateName": "Iron Chelating Agents",
"url": "https://questionsmedicales.fr/mesh/D007502",
"about": {
"@type": "MedicalCondition",
"name": "Agents chélateurs du fer",
"code": {
"@type": "MedicalCode",
"code": "D007502",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.720.832.500.410"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Sidérophores",
"alternateName": "Siderophores",
"url": "https://questionsmedicales.fr/mesh/D017262",
"about": {
"@type": "MedicalCondition",
"name": "Sidérophores",
"code": {
"@type": "MedicalCode",
"code": "D017262",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.720.832.500.410.750"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Sidérophores",
"alternateName": "Siderophores",
"url": "https://questionsmedicales.fr/mesh/D017262",
"about": {
"@type": "MedicalCondition",
"name": "Sidérophores",
"code": {
"@type": "MedicalCode",
"code": "D017262",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.720.832.500.410.750"
}
}
}
]
}
],
"about": {
"@type": "MedicalCondition",
"name": "Agents séquestrants",
"alternateName": "Sequestering Agents",
"code": {
"@type": "MedicalCode",
"code": "D064449",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Xueli Cao",
"url": "https://questionsmedicales.fr/author/Xueli%20Cao",
"affiliation": {
"@type": "Organization",
"name": "Beijing Advanced Innovation Center for Soft Matter Science and Engineering, State Key Laboratory of Chemical Resource Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China."
}
},
{
"@type": "Person",
"name": "Yu Xiao",
"url": "https://questionsmedicales.fr/author/Yu%20Xiao",
"affiliation": {
"@type": "Organization",
"name": "Ministry of Education Key Laboratory of Protein Science, Beijing Advanced Innovation Center for Structural Biology, Beijing Frontier Research Center for Biological Structure, School of Life Sciences, Tsinghua University, Tsinghua-Peking Center for Life Sciences, Beijing 100084, China."
}
},
{
"@type": "Person",
"name": "Erin Huiting",
"url": "https://questionsmedicales.fr/author/Erin%20Huiting",
"affiliation": {
"@type": "Organization",
"name": "Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94158, USA."
}
},
{
"@type": "Person",
"name": "Dong Li",
"url": "https://questionsmedicales.fr/author/Dong%20Li",
"affiliation": {
"@type": "Organization",
"name": "Beijing Advanced Innovation Center for Soft Matter Science and Engineering, State Key Laboratory of Chemical Resource Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China."
}
},
{
"@type": "Person",
"name": "Jie Ren",
"url": "https://questionsmedicales.fr/author/Jie%20Ren",
"affiliation": {
"@type": "Organization",
"name": "State Key Laboratory for Biology of Plant Diseases and Insect Pests, Ministry of Agriculture, Institute of Plant Protection, Chinese Academy of Agricultural Sciences, Beijing 100081, China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "KRAS and GNAS mutations in cell-free DNA and in circulating epithelial cells in patients with intraductal papillary mucinous neoplasms-an observational pilot study.",
"datePublished": "2024-09-01",
"url": "https://questionsmedicales.fr/article/39219164",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/1878-0261.13719"
}
},
{
"@type": "ScholarlyArticle",
"name": "CT imaging analysis differentiating papillary renal neoplasm with reverse polarity from papillary renal cell carcinoma: combined with a radiomics model.",
"datePublished": "2024-07-24",
"url": "https://questionsmedicales.fr/article/39046645",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s11604-024-01631-2"
}
},
{
"@type": "ScholarlyArticle",
"name": "Retrospective study of risk markers for developing high-grade anal intraepithelial neoplasm in men who have sex with men living with HIV.",
"datePublished": "2024-07-18",
"url": "https://questionsmedicales.fr/article/39032782",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ad.2024.05.026"
}
},
{
"@type": "ScholarlyArticle",
"name": "Oncocytic Type Has Distinct Immunohistochemical and Recurrence-Free Survival than Other Histologic Types of the Intraductal Papillary Neoplasm of the Bile Duct.",
"datePublished": "2024-05-21",
"url": "https://questionsmedicales.fr/article/38782100",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.humpath.2024.05.006"
}
},
{
"@type": "ScholarlyArticle",
"name": "Parotid squamous cell carcinoma metastases: Application of human papillomavirus -DNA test on liquid-based cytology to recognize oropharyngeal origin of the neoplasm.",
"datePublished": "2024-04-26",
"url": "https://questionsmedicales.fr/article/38676309",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/dc.25334"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Actions chimiques et utilisations",
"item": "https://questionsmedicales.fr/mesh/D020164"
},
{
"@type": "ListItem",
"position": 3,
"name": "Utilisations spécialisées de produits chimiques",
"item": "https://questionsmedicales.fr/mesh/D020313"
},
{
"@type": "ListItem",
"position": 4,
"name": "Agents séquestrants",
"item": "https://questionsmedicales.fr/mesh/D064449"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Agents séquestrants - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Agents séquestrants",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-03",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Agents séquestrants",
"description": "Comment diagnostiquer une intoxication aux métaux lourds ?\nQuels examens pour évaluer l'efficacité d'un agent séquestrant ?\nQuels symptômes indiquent un besoin d'agents séquestrants ?\nComment identifier une carence nutritionnelle ?\nQuels signes d'overdose d'agents séquestrants ?",
"url": "https://questionsmedicales.fr/mesh/D064449?mesh_terms=Prostatic+Neoplasms&page=1000#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Agents séquestrants",
"description": "Quels symptômes d'une carence en fer ?\nComment reconnaître une toxicité au plomb ?\nQuels signes d'une carence en calcium ?\nQuels symptômes d'une intoxication au mercure ?\nComment se manifeste une carence en potassium ?",
"url": "https://questionsmedicales.fr/mesh/D064449?mesh_terms=Prostatic+Neoplasms&page=1000#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Agents séquestrants",
"description": "Comment prévenir les carences nutritionnelles ?\nQuelles mesures pour éviter l'exposition aux métaux lourds ?\nComment réduire le cholestérol par l'alimentation ?\nQuels aliments riches en calcium pour la prévention ?\nComment éviter les effets secondaires des séquestrants ?",
"url": "https://questionsmedicales.fr/mesh/D064449?mesh_terms=Prostatic+Neoplasms&page=1000#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Agents séquestrants",
"description": "Quels agents séquestrants pour le cholestérol ?\nComment fonctionnent les agents séquestrants ?\nQuels sont les effets secondaires des agents séquestrants ?\nComment administrer un agent séquestrant ?\nQuels agents séquestrants pour les métaux lourds ?",
"url": "https://questionsmedicales.fr/mesh/D064449?mesh_terms=Prostatic+Neoplasms&page=1000#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Agents séquestrants",
"description": "Quelles complications d'une surconsommation d'agents séquestrants ?\nQuels risques d'une utilisation prolongée ?\nComment les agents séquestrants affectent-ils l'absorption des médicaments ?\nQuelles complications liées à l'intoxication au plomb ?\nQuels effets à long terme des agents séquestrants ?",
"url": "https://questionsmedicales.fr/mesh/D064449?mesh_terms=Prostatic+Neoplasms&page=1000#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Agents séquestrants",
"description": "Quels facteurs augmentent le risque de carences ?\nQui est à risque d'intoxication au mercure ?\nQuels groupes sont vulnérables aux carences en calcium ?\nQuels comportements augmentent le risque d'intoxication aux métaux ?\nQuels facteurs influencent l'absorption des nutriments ?",
"url": "https://questionsmedicales.fr/mesh/D064449?mesh_terms=Prostatic+Neoplasms&page=1000#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une intoxication aux métaux lourds ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins et urinaires peuvent détecter la présence de métaux lourds."
}
},
{
"@type": "Question",
"name": "Quels examens pour évaluer l'efficacité d'un agent séquestrant ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des analyses biochimiques peuvent mesurer les niveaux de nutriments ou toxines."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent un besoin d'agents séquestrants ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme des douleurs abdominales ou des troubles digestifs peuvent indiquer un besoin."
}
},
{
"@type": "Question",
"name": "Comment identifier une carence nutritionnelle ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins peuvent révéler des carences en vitamines ou minéraux."
}
},
{
"@type": "Question",
"name": "Quels signes d'overdose d'agents séquestrants ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des nausées, vomissements ou diarrhées peuvent signaler une overdose."
}
},
{
"@type": "Question",
"name": "Quels symptômes d'une carence en fer ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Fatigue, pâleur, essoufflement et vertiges sont des symptômes courants."
}
},
{
"@type": "Question",
"name": "Comment reconnaître une toxicité au plomb ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des douleurs abdominales, des troubles neurologiques et des anémies peuvent survenir."
}
},
{
"@type": "Question",
"name": "Quels signes d'une carence en calcium ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des crampes musculaires, des engourdissements et des troubles de l'humeur peuvent apparaître."
}
},
{
"@type": "Question",
"name": "Quels symptômes d'une intoxication au mercure ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tremblements, des troubles de la mémoire et des problèmes de vision peuvent se manifester."
}
},
{
"@type": "Question",
"name": "Comment se manifeste une carence en potassium ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des faiblesses musculaires, des palpitations et des troubles du rythme cardiaque peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment prévenir les carences nutritionnelles ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée et variée est essentielle pour éviter les carences."
}
},
{
"@type": "Question",
"name": "Quelles mesures pour éviter l'exposition aux métaux lourds ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter les aliments contaminés et utiliser des filtres à eau peut réduire l'exposition."
}
},
{
"@type": "Question",
"name": "Comment réduire le cholestérol par l'alimentation ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Consommer des fibres solubles et limiter les graisses saturées aide à réduire le cholestérol."
}
},
{
"@type": "Question",
"name": "Quels aliments riches en calcium pour la prévention ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les produits laitiers, les légumes verts et les noix sont de bonnes sources de calcium."
}
},
{
"@type": "Question",
"name": "Comment éviter les effets secondaires des séquestrants ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Prendre les agents séquestrants avec suffisamment d'eau et suivre les recommandations médicales."
}
},
{
"@type": "Question",
"name": "Quels agents séquestrants pour le cholestérol ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les résines comme le cholestyramine sont utilisées pour réduire le cholestérol sanguin."
}
},
{
"@type": "Question",
"name": "Comment fonctionnent les agents séquestrants ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils se lient aux substances dans l'intestin, empêchant leur absorption dans le sang."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires des agents séquestrants ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des effets comme des ballonnements, des nausées et des troubles digestifs peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment administrer un agent séquestrant ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils sont généralement pris par voie orale, souvent mélangés à des liquides."
}
},
{
"@type": "Question",
"name": "Quels agents séquestrants pour les métaux lourds ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des agents comme l'EDTA sont utilisés pour traiter les intoxications aux métaux lourds."
}
},
{
"@type": "Question",
"name": "Quelles complications d'une surconsommation d'agents séquestrants ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une surconsommation peut entraîner des carences nutritionnelles et des troubles digestifs."
}
},
{
"@type": "Question",
"name": "Quels risques d'une utilisation prolongée ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une utilisation prolongée peut causer des déséquilibres électrolytiques et des carences."
}
},
{
"@type": "Question",
"name": "Comment les agents séquestrants affectent-ils l'absorption des médicaments ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent réduire l'absorption de certains médicaments, diminuant leur efficacité."
}
},
{
"@type": "Question",
"name": "Quelles complications liées à l'intoxication au plomb ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications neurologiques, rénales et cardiovasculaires peuvent survenir."
}
},
{
"@type": "Question",
"name": "Quels effets à long terme des agents séquestrants ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des effets à long terme peuvent inclure des carences nutritionnelles et des troubles métaboliques."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque de carences ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation déséquilibrée, des maladies chroniques et des régimes restrictifs augmentent le risque."
}
},
{
"@type": "Question",
"name": "Qui est à risque d'intoxication au mercure ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les personnes consommant régulièrement des poissons contaminés sont à risque élevé."
}
},
{
"@type": "Question",
"name": "Quels groupes sont vulnérables aux carences en calcium ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les personnes âgées, les femmes enceintes et les végétariens peuvent être plus vulnérables."
}
},
{
"@type": "Question",
"name": "Quels comportements augmentent le risque d'intoxication aux métaux ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Travailler dans des environnements contaminés ou utiliser des produits non réglementés augmente le risque."
}
},
{
"@type": "Question",
"name": "Quels facteurs influencent l'absorption des nutriments ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'âge, la santé digestive et les interactions médicamenteuses influencent l'absorption."
}
}
]
}
]
}
Intraductal papillary mucinous neoplasms (IPMNs) are potential precursor lesions of pancreatic cancer. We assessed the efficacy of screening for KRAS proto-oncogene, GTPase (KRAS), and GNAS complex lo...
To assess the computed tomography (CT) findings of papillary renal neoplasm with reverse polarity (PRNRP) and develop a radiomics-based model to distinguish PRNRPs from papillary renal cell carcinomas...
We analyzed 31 PRNRPs and 68 PRCCs using preoperative kidney CT. We evaluated CT features that could discriminate PRNRPs from PRCCs. A radiomics signature was constructed using features selected throu...
Most of PRNRPs had a round shape (93.5%), well-defined margin (100%), and persistent enhancement (77.4%). Compared with PRCC, PRNRPs exhibited distinct CT features including small size (16.7 vs. 37.7 ...
Smaller tumor size, heterogeneity, and higher attenuation in pre-contrast CT were more closely associated with PRNRPs than with PRCCs. Though the retrospective design, small sample size, and single-ce...
High-grade anal intraepithelial squamous lesion is significantly prevalent among men who have sex with men and are infected with the human immunodeficiency virus. This condition-the precursor to anal ...
To describe a population of men who have sex with men living with human immunodeficiency virus followed in a specialized anal cancer screening unit we conducted an observational, retrospective, and si...
Ninety-four patients were analyzed, with a mean age of 39 ± 9 years, and a 87% positivity rate for high-risk human papillomavirus (HR-HPV). At the initial visit, 47% presented with low-grade squamous ...
In this series, longer duration of HIV infection, tobacco and alcohol use and the presence of HR-HPV were significantly associated with the occurrence of high-grade intraepithelial lesions. A lower ri...
In men who have sex with men living with HIV, the association of factors such as smoking, alcohol, the presence of HR-HPV and an increased burden of human papillomavirus disease makes these patients m...
Although intraductal oncocytic papillary neoplasm (IOPN) was considered distinct from the intraductal papillary neoplasm of the pancreas, the oncocytic histologic type remained as a subtype of intradu...
Malignancies of the parotid gland are relatively uncommon and in most cases are primary neoplasms; intraparotid metastases are rare. Oral and oropharyngeal squamous cell carcinoma (O- and OP-SCC) can ...
Malignant basaloid neoplasms of the skin are frequent, and their accurate diagnosis holds paramount importance for treatment and prognosis. However, these neoplasms can present diagnostic challenges b...
The potential for more than one distinct hematolymphoid neoplasm to arise from a common mutated stem or precursor cell has been proposed based on findings in primary human malignancies. Particularly, ...
To identify MRI features for differentiating type 2 from type 1 intraductal papillary neoplasms of bile duct (IPNB) and assessing malignant potential of IPNB....
This retrospective study included 60 patients with surgically proven IPNB who had undergone preoperative MRI between January 2007 and December 2020. All surgical specimens were reviewed retrospectivel...
An associated invasive carcinoma was more frequently found in type 2 than in type 1 IPNB (85.0% [34/40] vs. 45.0% [9/20], p = 0.003). At univariable analysis, MRI features including extrahepatic locat...
MRI with MR cholangiopancreatography may be helpful in differentiating type 2 IPNB from type 1 IPNB and assessing malignant potential of IPNB....
Preoperative MRI with MR cholangiopancreatography may be helpful in differentiating type 2 intraductal papillary neoplasms of bile duct (IPNB) from type 1 IPNB and assessing malignant potential of IPN...
• In terms of tumor grade, the incidence of invasive carcinoma was significantly higher in type 2 intraductal papillary neoplasm of the bile duct (IPNB) than in type 1 IPNB. • At MRI, extrahepatic loc...
Gastrointestinal Neuroendocrine Neoplasms (GI-NENs) often result in liver metastases, and the role of Primary Tumor Resection (PTR) in managing GI-NENs with liver metastases (GI-NENLM) is still debate...
The SEER Registry 17 database and the FAH clinical pathology database were used to collect clinicopathology data for GI-NENLM diagnosed between 2010 and 2019 and between 2011 and 2022, respectively. P...
After matching, 155 patients from the SEER database were matched to the FAH cohort. PTR was significantly associated with better prognosis in PSM-matched/unmatched SEER cohorts (P < 0.01) and in the F...
The employment of PTR in patients with GI-NENLM is significantly correlated with individual survival benefits. We support performing PTR on carefully evaluated patients....
The process of post-transcriptional regulation has been recognized to be significantly impacted by the presence of N6-methyladenosine (m6A) modification. As an m6A demethylase, ALKBH5 has been shown t...